Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies — Meletios A Dimopoulos (2019) | RDL Network
Ixazomib maintenance following ixazomib-based induction is associated with deepening of responses and a positive safety profile with no cumulative toxicity in patients with NDMM not undergoing transplantation, suggesting that ixazomib is feasible for long-term administration. Phase III investigation of ixazomib maintenance is ongoing.
Wee Joo Chng, Meral Beksaç, Roman Hájek, Katja Weisel, María‐Victoria Mateos, Andrew Spencer, Shinsuke Iida, Danielle de Farias, Richard Labotka, Tomáš Skácel, Antonio Palumbo, Sagar Lonial, Shaji Kumar, Meletios A Dimopoulos
Meletios A Dimopoulos, Ivan Špıčka, Hang Quach, Albert Oriol, Roman Hájek, Mamta Garg, Meral Beksaç, Sara Bringhen, Eirini Katodritou, Wee Joo Chng, Xavier Leleu, Shinsuke Iida, María‐Victoria Mateos, Gareth J. Morgan, Alexander Vorog, Richard Labotka, Bingxia Wang, Antonio Palumbo, Sagar Lonial
Meletios A Dimopoulos, Andrzej Jakubowiak, Philip L. McCarthy, Robert Z. Orlowski, Michel Attal, Joan Bladé, Hartmut Goldschmidt, Katja Weisel, Karthik Ramasamy, Sonja Zweegman, Andrew Spencer, Jeffrey Huang, Jin Lu, Kazutaka Sunami, Shinsuke Iida, Wee Joo Chng, Sarah A. Holstein, Alberto Rocci, Tomáš Skácel, Richard Labotka, Antonio Palumbo, Kenneth C. Anderson
Meletios A Dimopoulos, Ivan Špıčka, Hang Quach, Albert Oriol, Roman Hájek, Mamta Garg, Meral Beksaç, Sara Bringhen, Eirini Katodritou, Wee Joo Chng, Xavier Leleu, Shinsuke Iida, María‐Victoria Mateos, Gareth J. Morgan, Alexander Vorog, Richard Labotka, Bingxia Wang, Antonio Palumbo, Sagar Lonial
Hartmut Goldschmidt, Meletios A Dimopoulos, S. Vincent Rajkumar, Katja Weisel, Philippe Moreau, Wee Joo Chng, Gábor Mikala, Michèle Cavo, Karthik Ramasamy, Kaveri Suryanarayan, Zhaoyang Teng, Richard Labotka, María‐Victoria Mateos
Discussion(0)
No comments yet. Be the first to comment.